MNG797
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.502
- E2F_TARGETS+0.423
- MYC_TARGETS_V2+0.408
- MITOTIC_SPINDLE+0.393
- UNFOLDED_PROTEIN_RESPONSE+0.317
- MYC_TARGETS_V1+0.305
- OXIDATIVE_PHOSPHORYLATION+0.245
- PROTEIN_SECRETION+0.186
- MTORC1_SIGNALING+0.178
- GLYCOLYSIS+0.163
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.500
- INTERFERON_GAMMA_RESPONSE-0.485
- APICAL_SURFACE-0.423
- IL6_JAK_STAT3_SIGNALING-0.418
- TNFA_SIGNALING_VIA_NFKB-0.412
- INTERFERON_ALPHA_RESPONSE-0.402
- COAGULATION-0.395
- INFLAMMATORY_RESPONSE-0.374
- KRAS_SIGNALING_UP-0.345
- P53_PATHWAY-0.288
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1195 | — | — | 0.916 |
| 2 | MNG1194 | — | — | 0.914 |
| 3 | b09c5d28-8a02-4343-b678-07cbf351ed44 | — | — | 0.902 |
| 4 | SRR13780247 | — | cohortMD1 | 0.901 |
| 5 | TCGA-78-7155-01A-11R-2039-07 | — | cohortMD1 | 0.896 |
| 6 | SRR5088887 | — | — | 0.895 |
| 7 | SRR10899994 | — | — | 0.895 |
| 8 | TCGA-86-8054-01A-11R-2241-07 | — | cohortA3 | 0.894 |
| 9 | SRR8613725 | — | E | 0.891 |
| 10 | BS_M84H3KXA | medulloblastoma | — | 0.890 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.502 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.423 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.408 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.393 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.317 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.305 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.245 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.186 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.178 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.163 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.134 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.133 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.133 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| ADIPOGENESIS | 0.064 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.060 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.049 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.012 | Inavolisib | — uncovered |